Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

This study tests a new imaging technique that uses a specially labeled antibody (panitumumab-IRDye800) injected before surgery to help surgeons see and identify cancer tissue in real-time during lung surgery, potentially improving how completely cancer can be removed. **You may be eligible if...** - You have a suspicious lung nodule or mass that may be cancer (primary lung cancer or a lung metastasis), with or without a prior biopsy - You are scheduled for standard surgery to remove the lung nodule or mass - You are in adequate physical condition (Karnofsky score at least 70%, or ECOG level 0–2) - Your blood counts (hemoglobin, white blood cells, platelets) meet the required minimums - Your kidney function is within acceptable range **You may NOT be eligible if...** - You are not scheduled for lung surgery - Your blood counts or kidney function are too low to meet the eligibility requirements Talk to your doctor to see if this trial is right for you.